. Introduction {#s01}
==============

As a subtype of breast cancer, triple-negative breast cancer (TNBC) is defined by the lack of estrogen receptors (ERs), progesterone receptors (PRs), and the human epidermal growth factor receptor 2 (HER2). The TNBC constitutes up to 15% to 20% of all pathological types of breast cancer, with a tendency towards aggressive behavior, clinically shown by younger onset age, higher histological grade and distant metastasis rate, as well as poorer prognosis^[@b1]^. As the TNBC patients are not eligible for conventional targeted therapies for lacking the molecular target renders, chemotherapy based on anthracyclines and taxanes is currently the main post-surgical therapeutic strategy^[@b2]^. However, the recurrence rate in patients with TNBC remains at a high level, leading to a significant decline in survival rate in the initial 3 to 5 years after surgery^[@b3]^. Therefore, exploring novel therapeutic strategies is an important clinical challenge in treating TNBC.

Based on the gene expression data, TNBC was categorized by Lehmann et al.^[@b4]^ into 6 subtypes, including basel-like 1 and 2 (BL1 and BL2), mesenchymal (M), immunomodulatory (IM), mesenchymal stem-like (MSL), and luminal androgen receptor (LAR). TNBC is a heterogeneous disease with varied sensitivity to different therapies. The IM subtype (featured by enhanced expression of immune genes) indicates that immune-based therapies might be beneficial to some of the TNBC patients^[@b5]^. Therefore, chemotherapies coupled with immunotherapies may be considered as an alternative option for treating TNBC patients.

The principle of adoptive immunotherapy is to collect the immune cells from the human body, and then transmit them back to the human body for anti-tumor activity, after an *in vitro* transformation and expansion. Cytokine-induced killer (CIK) cells are defined as a subset of cytotoxic T lymphocytes with an immunophenotype of CD3^+^CD56^+^. The CIK cells have been proven to be ideal for use in immunotherapy as they can reproduce rapidly outside the human body and directly kill tumor cells^[@b6]^, thereby regulating and enhancing host cell immune function *in vivo*^[@b7]^. Compared with another cytotoxic effector T cells, named lymphokine-activated killer (LAK) cells, the CIK cells present enhanced tumor cell lytic activity and reproduction rate, and lowered toxicity^[@b8]^. Subsequently, CIK cell-based therapy has been broadly adopted as an adjuvant treatment combined with chemotherapy for treating multiple types of cancers, such as renal cell carcinoma^[@b9]^, gastric cancer^[@b10]^, non-small cell lung cancer^[@b11]^, colon cancer^[@b12]^, and liver cancer^[@b13]^, with great efficacy and safety.

However, a few studies have been conducted on the efficacy of CIK treatment in breast cancer, especially in TNBC. The existing clinical studies on treating breast cancer with CIK cells have mostly concentrated on advanced or metastatic breast cancer^[@b14]-[@b17]^. These studies have shown that CIK cell therapy can be used as a rescue therapy to facilitate the prognosis of advanced or metastatic breast cancer, and to improve the patient's quality of life. Therefore, a clinical retrospective study regarding the efficacy of CIK cell therapy on the prognosis of postoperative TNBC patients was performed.

. Materials and methods {#s02}
=======================

. Patients {#s02.01}
----------

A retrospective study was conducted to examine the clinical outcomes of autologous CIK immunotherapy in TNBC patients after surgery. The patients were recruited to the study from January 1, 2009 to January 1, 2015. In the CIK group, 147 postoperative TNBC patients received autologous CIK cells after chemotherapy. Concomitantly, 147 participants (control group) were selected that received chemotherapy alone after the surgery, and also matched with age ± 1 year to the index patients. The following is the brief outline of patient enrollment procedure in the control group: Initially, between January 1, 2009 and January 1, 2015, a review of the medical records of patients diagnosed with TNBC from a computerized database in our hospital was performed; then, the matching cases were selected in accordance with the enrollment and exclusion criteria; finally, matching patients with same age as those in CIK group were chosen; if there is no same-aged case as that of patients in CIK group, the cases with age ±1 were selected randomly; if there are more than one same-aged cases, then one case was selected randomly by random number method.

The following were the inclusion criteria for selecting patients: 1) The selected patients must be histologically diagnosed with TNBC. TNBC is defined by the immunohistochemical staining feature of ER, PR, and HER2. The staining feature categorization is as follow: ER and PR negative is defined as ER and PR staining \< 1%; HER2 negative is defined as HER2 staining 0 to 2+ by, or a nonamplified HER2 by fluorescence *in situ* hybridization (FISH); 2) No occurrence of distant metastasis prior to surgery; 3) Absence of other malignant tumor; 4) Karnofsky performance status score higher than 70 %; 5) Reception of CIK treatment before disease progression. The exclusion criteria were as below: 1) absence of adjuvant chemotherapy, or inability to tolerate or complete the chemotherapy due to serious adverse reactions; 2) severe disease of heart, lung, liver or kidney, bone marrow dysfunction, autoimmune diseases; 3) pregnancy or lactation. Guided by the Declaration of Helsinki, this study has been authorized by the Ethics Committee of Tianjin Medical University Cancer Institute and Hospital (Approval No. bc2019024) and by the State Food and Drug Administration of China (No. 2006L01023). The detailed clinical characteristics of patients in the both groups are shown in the **[Supplementary Table S1](#Table1){ref-type="table"}**.

###### 

Clinical characteristics of patients in the two groups

  Characteristics                    CIK group   Control group   *P*
  ---------------------------------- ----------- --------------- -------
  Patients, *n*                      147         147             
  Age (years)                                                    1.000
  　\< 35                            9           9               
  　≥ 35                             138         138             
  Tumor size (cm)                                                0.644
  　≤ 2                              64          68              
  　\> 2, ≤ 5                        65          58              
  　\> 5                             11          14              
  　Unable to value                  7           7               
  Lymph node metastasis                                          0.338
  　Yes                              53          61              
  　No                               94          86              
  TNM stage                                                      0.064
  　I                                46          43              
  　IIa                              56          56              
  　IIb                              23          11              
  　IIIa                             5           14              
  　IIIb                             1           2               
  　IIIc                             9           15              
  　Unable to value                  7           6               
  Histological grade                                             0.365
  　1                                0           2               
  　2                                89          88              
  　3                                58          57              
  Pathological type                                              0.069
  　Invasive ductal carcinoma        138         129             
  　Others                           9           18              
  Surgery                                                        0.469
  　Radical mastectomy               24          17              
  　Modified radical mastectomy      110         118             
  　Breast-conserving surgery        13          12              
  Radiotherapy                                                   0.162
  　Yes                              38          28              
  　No                               109         119             
  Neoadjuvant chemotherapy                                       1.000
  　Yes                              21          21              
  　No                               126         126             
  Adjuvant chemotherapy regimens                                 0.319
  　Anthracycline-based              17          10              
  　Anthracycline-and taxane-based   113         122             
  　Taxane-based                     17          15              

. Treatments {#s02.02}
------------

All participating patients underwent modified radical mastectomy, radical mastectomy, or breast-conserving surgery. Postoperatively, these patients underwent 4 to 8 cycles of standard adjuvant chemotherapy in accordance with the NCCN Clinical Practice Guidelines in Oncology. Chemotherapy regimens involved anthracycline-based \[AC (adriamycin 60 mg/m^2^, cyclophosphamide 600 mg/m^2^ d1, 21 days a cycle) or EC (epirubicin 90 mg/m^2^, cyclophosphamide 600 mg/m^2^ d1, 21 days a cycle) or CAF (5-Fu 500 mg/m^2^, adriamycin 50 mg/m^2^, cyclophosphamide 500 mg/m^2^ d1, 21 days a cycle) or CEF (5-Fu 500 mg/m^2^, epirubicin 100 mg/m^2^, cyclophosphamide 500 mg/m^2^ d1, 21 days a cycle)\], anthracycline- and taxane-based \[TAC (docetaxel 75 mg/m^2^, adriamycin 50 mg/m^2^, cyclophosphamide 500 mg/m^2^ d1, 21 days a cycle) or AC-T (adriamycin 60 mg/m^2^, cyclophosphamide 600 mg/m^2^ d1, 4 cycles, docetaxel 80-100 mg/m^2^ d1, 4 cycles, 21 days a cycle)\], or taxane-based \[TC (docetaxel 75 mg/m^2^, cyclophosphamide 600 mg/m^2^ d1, 21 days a cycle)\] regimens.

It was observed that some patients received neoadjuvant chemotherapy or adjuvant radiotherapy based on their clinical stage and operation. For all patients who are diagnosed with invasive breast cancer and choose breast-conserving surgery, whole breast radiotherapy (RT) is recommended. In cases of adjuvant RT after radical/modified radical mastectomy, radiation should be administered mainly to the ipsilateral chest wall and supraclavicular region on the same side as the tumor in patients with four or more positive axillary nodes, or with tumor ≥ 5 cm; for the patients with negative nodes or those with tumors \< 5 cm, the guidelines recommend radiation to the chest wall. Patients with small tumors and no nodal involvement do not need to undergo radiation therapy. RT is administered to the chest wall with 6 MV X-ray at a total dose of 45-50 Gy with 1.8-2.0 Gy/fraction, 5 fractions/week. Introducing a boost to the tumor bed for patients with greater risk (age \< 50 and high-grade disease) using doses of 10-16 Gy at 2 Gy/fx is recommended.

. CIK cells preparation and injection {#s02.03}
-------------------------------------

At least 2 weeks after the patients completed post-mastectomy chemotherapy (with/without radiotherapy) and when routine blood count returned to normal, 50 mL of peripheral blood samples were collected for the preparation of CIK cells. The previously published research^[@b9],\ [@b12],\ [@b18]-[@b20]^ has provided the detailed method of CIK preparation. In brief, to gather the peripheral blood mononuclear cells (PBMCs) from TNBC patients, a COBE Spectra Apheresis System was used. The PBMCs were then cultured in a medium containing 1000 U/mL interferon-γ (IFN-γ), 100 U/mL recombinant human interleukin-1α (IL-1α), and 50 ng/mL anti-CD3 antibody, with 5% CO~2~ at 37 °C for 24 h, followed by the addition of 300 U/mL of recombinant human IL-2 to the medium. This medium was constantly replaced with a fresh medium containing IFN-γ and IL-2 every 5 days. By using this approach, a cellular subset with noticeably higher CD3^+^CD56^+^ was prepared. On the 14^th^ day, the CIK cells were harvested. Eventually, over 5 × 10^9^ of CIK cells with \> 95% viability were obtained. No fungus, mycoplasma, or bacteria were found in the reagents.

In the CIK group, on day 15 and day 16 of each chemotherapy cycle, patients received an intravenous infusion of at least 5 × 10^9^ CIK cells. During the input, routine body indexes, such as body temperature, heart rate, respiration, blood pressure, and other basic vital signs, were monitored. Maintenance treatment was accessible to these patients unless they refused to proceed or in case of recurrence or distant metastasis.

. Follow-up and clinical assessment {#s02.04}
-----------------------------------

From the date of surgery until May 1, 2018 or death, a follow-up was performed for all the patients. The median follow-up time was 75 months (ranging from 39-110 months). The overall survival (OS) and disease-free survival (DFS) were defined in accordance with the National Cancer Institute's Response Evaluation Criteria in Solid Tumors (RECIST)^[@b21]^. OS was measured from the date of surgery until decease and living patients were examined at the time of the last follow-up. DFS was calculated from the date of surgery until first recurrence or metastasis, or death from any cause. Patients that achieved a stable state were evaluated at the final follow-up. Besides, based on the criteria specified by the World Health Organization (WHO), adverse clinical activities were monitored and evaluated.

In the initial 2 years after the surgery, the follow-up was conducted in a 3-month cycle. The interval was extended to 6 months from year 2 through year 5, and annually thereafter. The reviewed patient records included breast ultrasound, breast tumor markers, mammography, X-ray or computed tomography (CT) on the chest, liver and abdomen ultrasound, bone scan, and head magnetic resonance imaging (MRI) if necessary. In this study, telephonic consultation was offered to each patient and no loss to follow-up was experienced.

. Statistical analysis {#s02.05}
----------------------

The Chi-square and Fisher's exact tests were used to analyze the differences in variables of the two groups, in terms of both demographic and clinical characteristics. The Kaplan-Meier method was used to evaluate the survival time and rate distribution. The log-rank test univariate analyses were used to assess the relationship between survival and the potential prognostic factors. This was further verified by the multivariate analysis of Cox proportional hazards regression. Further, SPSS 20.0 software was used as a tool to analyze all the calculations. Statistical significance was considered at two-tailed *P* \< 0.05 for all the calculations.

. Results {#s03}
=========

. Patients' characteristics {#s03.01}
---------------------------

This retrospective analysis involved total 294 patients, with 147 members in each group (CIK and control group). Each participant was compared to the matching patient from the other group for the time of diagnosis, age at onset of disease, pathological type, tumor size, TNM stage and regional lymph node metastasis at the first visit, operation and treatment, and subsequent therapies. It was found that there were no statistically significant differences between the two groups (*P* \> 0.05). **[Table 1](#Table1){ref-type="table"}** shows the data for all the patients.

. Survival analysis {#s03.02}
-------------------

It was observed that the patients in the CIK group experienced significantly longer DFS intervals than their counterparts in the control group (*P* = 0.047, **[Figure 1A](#Figure1){ref-type="fig"}**). DFS rates of the CIK and control group after 1-, 3-, and 5-year intervals were 99.3% *vs*. 95.9%, 91.8% *vs*. 83.7%, and 88.1% *vs*. 81.3%, respectively. Similarly, the OS interval of the CIK group was significantly longer than that of the control group (*P* = 0.007, **[Figure 1B](#Figure1){ref-type="fig"}**), and the 1-, 3-, and 5-year OS rates of the CIK and control group were 99.3% *vs*. 98.0%, 96.6% *vs*. 91.8%, and 93.4% *vs*. 84.1%, respectively. Therefore, compared to the control group patients treated with adjuvant chemotherapy (with or without radiotherapy), post-mastectomy TNBC patients, who received additional sequential CIK treatment, had significantly improved DFS and OS rates. In the CIK group, the median courses of CIK treatment were 6 cycles (range 1-26 cycles). Patients undergoing ≥ 6 cycles of CIK cell therapy had greater DFS (*P* = 0.020, **[Figure 2A](#Figure2){ref-type="fig"}**) and OS (*P* = 0.040, **[Figure 2B](#Figure2){ref-type="fig"}**) rates than those treated with \< 6 cycles. Therefore, it can be inferred that longer CIK treatment courses are associated with better prognosis.

![Survival analysis of patients in cytokine-induced killer (CIK) group and control group. (A) Disease-free disease-free survival (DFS) curves. (B) Overall survival (OS) curves. The Kaplan-Meier method was used to compare the DFS and OS between the CIKgroup and control group.](cbm-16-2-350-1){#Figure1}

![Prognostic impact of the frequency of cytokine-induced killer (CIK) treatment on patients in the CIK group. (A) Disease disease-free survival (DFS) curves. (B) Overall survival (OS) curves. The Kaplan-Meier method was used to compare the survival rates between the patients in the CIK group underwent ≤ 6 cycles CIK cells injection and the patients in the CIK group underwent \> 6 cycles CIK cells injection.](cbm-16-2-350-2){#Figure2}

Until the completion of follow-up, recurrence or metastasis was observed in 16 patients in the CIK group, and 29 patients in the control group. Statistically, the two groups had no difference in the metastatic sites or the number of sites. It was found that the most common sites of distant metastases were the bone, lung, liver, and brain (**[Table 2](#Table2){ref-type="table"}**).

###### 

The details of recurrence and metastasis between the two groups

                                CIK group (*n* = 16)   Control group (*n* = 29)   *P*
  ----------------------------- ---------------------- -------------------------- -------
  Sites                                                                           0.581
  　Chest wall                  3/16 (18.8%)           6/29 (20.7%)               
  　Regional lymph node         4/16 (25.0%)           5/29 (17.2%)               
  　Lung                        6/16 (37.5%)           12/29 (41.4%)              
  　Bone                        6/16 (37.5%)           9/29 (31.0%)               
  　Liver                       3/16 (18.8%)           5/29 (17.2%)               
  　Brain                       3/16 (18.8%)           4/29 (13.8%)               
  　Other sites                 1/16 (6.3%)            2/29 (6.9%)                
  Numbers of metastatic sites                                                     0.628
  　1                           7/16 (43.7%)           14/29 (48.3%)              
  　2                           1/16 (6.3%)            4/29 (13.8%)               
  　≥ 3                         8/16 (50.0%)           11/29 (37.9%)              

. Subgroup analysis {#s03.03}
-------------------

Further study was conducted to analyze the TNM stages of the patients that received better benefits from the CIK cell treatment. For this, all 294 patients were divided into an early-stage group (I, IIa stage) and a late-stage group (IIb, III stage), and a survival analysis of each subgroup was conducted. It was observed that the OS of TNBC patients in the early-stage group was extended by CIK treatment (*P* = 0.018, **[Figure 3B](#Figure3){ref-type="fig"}**). However, such results were not obtained for the DFS (*P* = 0.081, **[Figure 3A](#Figure3){ref-type="fig"}**; *P* = 0.114, **[Figure 3C](#Figure3){ref-type="fig"}**) or the OS of late-stage TNBC patients (*P* = 0.054, **[Figure 3D](#Figure3){ref-type="fig"}**).

![(A) Subgroup analysis to estimate the benefits of CIK treatment according to TNM stages. A, disease-free survival (DFS) curves of TNBC patients with stage I, IIa. (B) Subgroup analysis to estimate the benefits of CIK treatment according to TNM stages. B, overall survival (OS) curves of TNBC patients with stage I, IIa. (C) Subgroup analysis to estimate the benefits of CIK treatment according to TNM stages. A, disease-free survival (DFS) curves of TNBC patients with stage IIb, III. (D) Subgroup analysis to estimate the benefits of CIK treatment according to TNM stages. B, overall survival (OS) curves of TNBC patients with stage IIb, III.](cbm-16-2-350-3){#Figure3}

. Prognosis analysis {#s03.04}
--------------------

In the univariate and multivariate analysis, the impact of CIK treatment on the prognosis of post-surgery patients with TNBC was further evaluated. It was revealed by the log-rank test univariate analysis that the size of a tumor, TNM stage, lymph node metastasis, histological grade, radiotherapy, and CIK treatment were the prognostic factors influencing DFS and OS in TNBC patients. Additional Cox multivariate analysis showed that for TNBC patients, the adjuvant CIK treatment and TNM stage remained independent prognostic factors for both DFS (CIK treatment: HR = 0.520, 95% CI:0.271-0.998, *P* = 0.049; TNM stage: HR = 1.449, 95% CI:1.118-1.877, *P* = 0.005, respectively) and OS (CIK treatment: HR = 0.414, 95% CI:0.190-0.903, *P* = 0.027; TNM stage: HR = 1.581, 95% CI:1.204-2.077, *P* = 0.001, respectively, **[Table 3](#Table3){ref-type="table"}**).

###### 

Multivariate analysis of DFS and OS in patients with TNBC

  Parameter               DFS                               OS                         
  ----------------------- --------------------- ----------- ---- --------------------- -----------
  TNM stage               1.449 (1.118-1.877)   0.005^\*^        1.581 (1.204-2.077)   0.001^\*^
  Tumor size              1.943 (0.847-4.459)   0.117            2.018 (0.761-5.352)   0.158
  Lymph node metastasis   1.001 (0.426-2.352)   0.998            1.258 (0.465-3.403)   0.652
  Histological grade      1.510 (0.821-2.778)   0.185            1.576 (0.796-3.119)   0.191
  Radiotherapy            0.578 (0.198-1.692)   0.317            0.738 (0.209-2.605)   0.637
  CIK treatment           0.520 (0.271-0.998)   0.049^\*^        0.414 (0.190-0.903)   0.027^\*^

. Toxic and side effects {#s03.05}
------------------------

Adverse reactions during the treatment in both groups of patients were observed. Both groups experienced common adverse reactions, including myelosuppression, fever, nausea and vomiting, liver dysfunction, kidney dysfunction, and the peripheral nerve toxicity. The main adverse reactions were I to II degrees. In the III-IV-degree myelosuppression group, 11 were in the CIK group and 12 in the control group; the side effects of the digestive tract were within the III degree; fever, renal impairment, and neurotoxicity were of I-II degrees. No intolerable adverse reactions were observed in both the groups, and no statistical difference was observed on comparing the adverse events between two groups (**[Table 4](#Table4){ref-type="table"}**). There were no obvious adverse reactions observed during the injection of CIK cells. In the CIK group, 11 patients had a transient fever reaction (temperature \< 38.5°C) that returned to normal condition within 24 h after symptomatic treatment. Moreover, during the course of CIK cell treatment, no patient quit midway due to intolerant side effects.

###### 

Adverse events of the two groups

  ------------------------------------------------------------------
  Adverse events              CIK group\    Control group\   *P*
                              (*n* = 147)   (*n* = 147)      
  --------------------------- ------------- ---------------- -------
  Bone marrow suppression                   0.222            

  　0                         98            84               

  　I                         20            35               

  　II                        18            16               

  　III                       8             10               

  　IV                        3             2                

  Fever                                                      0.491

  　0                         118           112              

  　I                         28            32               

  　II                        1             3                

  　III                       0             0                

  　IV                        0             0                

  Nausea and vomiting                       0.545            

  　0                         98            94               

  　I                         18            13               

  　II                        23            31               

  　III                       8             9                

  　IV                        0             0                

  Liver dysfunction                                          0.641

  　0                         120           117              

  　I                         17            21               

  　II                        10            8                

  　III                       0             1                

  　IV                        0             0                

  Kidney dysfunction                        0.415            

  　0                         137           134              

  　I                         9             13               

  　II                        1             0                

  　III                       0             0                

  　IV                        0             0                

  Peripheral nerve toxicity                 0.542            

  　0                         132           126              

  　I                         10            13               

  　II                        5             8                

  　III                       0             0                

  　IV                        0             0                
  ------------------------------------------------------------------

. Discussion {#s04}
============

Compared to the non-triple-negative breast cancers, TNBC shows more biological aggression. It is also associated with poorer prognosis and shorter survival time^[@b1]^. On account of the stronger antigenicity owing to genomic instability and tumor mutation load, as well as higher expression of tumor infiltrating lymphocytes (TILs)^[@b22]^, and programmed death-ligand 1 (PD-L1)^[@b23]^ in TNBC make them a suitable target for immunotherapy, in contrast to the other subtypes of breast cancer. As the immunotherapy is non-organ-specific or non-tumor-specific, it is important to find the proper patient and treatment time, while combining it with existing treatment to achieve maximum efficacy. A breakthrough was achieved recently as immune checkpoint inhibitors (anti-PD-1 and anti-PD-L1 antibodies^[@b24],\ [@b25]^) became clinically effective. These previous significant studies have encouraged us to conduct the retrospective research on the effectiveness and safety of autologous CIK cell therapy coupled with chemotherapy in TNBC patients.

We found that CIK treatment combined with chemotherapy could effectively reduce the recurrence and metastasis in TNBC patients, thereby prolonging overall survival, and it had a stronger effect on patients at relatively early-stage of the disease. The conclusion that the patients in the early stages are the ones most benefited from CIK treatment was in line with some of the results from available studies on the treatment of other early-stage tumors by CIK immune cells^[@b26],\ [@b27]^. Several mechanisms could further contribute to the observed phenomenon. On one hand, the immune function of patients with late-stage cancer could be suppressed by the heavy tumor burden, which also influences the activity of infused CIK cells^[@b28]^. Immune system suppression related to tumor stages may hinder the initial expansion of CIK cells^[@b29]^. On the other hand, to evade the immune surveillance or immunotherapy, late-stage cells of metastatic cancer may evolve at molecular level^[@b30]^. Relevant information that could contribute to preventing recurrence and metastasis in early-stage TNBC patients using the new immunotherapy protocol is provided in the study.

Sequential CIK cell therapy after adjuvant chemotherapy resulted in dramatic lengthening of both DFS and OS intervals compared to those after chemotherapy alone, with a median DFS of 59 versus 55 months, and a median OS of 60 versus 59 months, respectively. The therapeutic model of cytotoxic chemotherapy combined with immunotherapy has been supported by some preclinical studies. These studies have shown that there is a synergy and complementation relationship between immunotherapy and chemotherapy^[@b31]^. The left-out tumor cells after chemotherapy and some chemotherapy-insensitive tumor cells can be removed by CIK cells^[@b32]^. Furthermore, it was demonstrated in previous studies that CIK cells could function as anti-cancer stem cells^[@b33]^. In this way, CIK cell therapy can reduce tumor recurrence and metastasis. Additionally, CIK cells secrete cytokines, such as IFN-γ, IL-2, and TNF-α, which can activate the anti-tumor properties of macrophages, reduce the immunological damage resulting from chemotherapeutic drugs, and facilitate the immune surveillance function of the body, to inhibit the growth of tumor cells^[@b34]^. Some chemotherapeutics, such as anthracycline can not only kill tumor cells directly, but also increase the sensitivity of tumor cells to immune effector cells^[@b35]^, thereby promoting their eradication by immune cells. With weakly immunogenic and immunosuppressive properties, immune escape is a typical biological feature of tumor cells^[@b36]^. Regulatory T (Treg) cells could limit the anti-tumor effect of immune cells by hindering CD3^+^CD4^+^ and CD3^+^CD8^+^ T lymphocytes from activation and proliferation, preventing NK cells proliferation, producing inhibitory cytokines, and eliminating effector cells, thereby promoting the immune escape of tumor cells, thus stimulating tumor progression^[@b37]^. CIK cells are capable of decreasing Treg cells ratio in peripheral blood of tumor patients, thereby increasing the proportion of CD3^+^CD4^+^T cells and the ratio of CD4^+^/CD8^+^T cells, thus the immunosuppressive status of tumor patients could be reduced or eliminated^[@b38]^. Therefore, chemotherapy can significantly lower the tumor burden, and then immune suppression can be alleviated or restored, hence sequential immunotherapy could achieve better therapeutic efficacy.

Additionally, besides the synergic effect with chemotherapy, immunotherapy also shows synergy with radiotherapy. Preclinical and clinical evidence suggests that RT may be a motivating factor to enhance the therapeutic benefits of immunotherapy for cancers^[@b39],\ [@b40]^.The potential effects of radiotherapy combined with immunotherapy are complex and multifactorial. Briefly, a combination of RT and immunotherapy induces the release of antigens during cancer cell death in association with proinflammatory signals that trigger the innate immune system to activate the tumor-specific T cells; thus, tumor targeted radiation therapy can be converted into an *in-situ* tumor vaccine^[@b41]^. To summarize, RT could improve the efficacy of immunotherapy and the immune system also functions in the action of radiotherapy.

No significant difference was found in the adverse reactions to chemotherapy plus CIK immunotherapy or chemotherapy alone, which indicates that the adverse effects of CIK immunotherapy are minor. The number of cycles for CIK treatment in this study depended on the patient's disease progression, willingness to treat, and family economic status, ranging from 1 to 26 cycles, with the median of 6 treatment cycles. Survival analysis showed that the patients treated for more than 6 cycles with CIK cells had greater DFS and OS intervals than those treated with less than 6 cycles, demonstrating that the prognosis of patients was related to the frequency of CIK administration. However, the specific connection between the number of CIK treatment cycles and survival remains to be explored. Furthermore, the equilibrium of treatment efficacy and costs, and the exploration of the number of cycles to the greatest benefit of patients remains to be studied.

The study was novel for a number of reasons. First, the objects of the study were TNBC patients without distant metastasis, which forms a complementation with existing clinical studies of the patients at an advanced stage of breast cancer or metastatic breast cancer using CIK cells for treatment^[@b14]-[@b17]^. Therefore, this study enhanced our understanding of the potential of CIK cells in breast cancer treatment. Additionally, previous studies mostly concentrated on treatment using a single chemotherapy regimen^[@b42]^; in this study, the chemotherapy regimens were classified into anthracycline-based, anthracycline- and taxane-based, and taxane-based regimens, which provided a more comprehensive description of the efficacy of CIK cell therapy. However, this study also has some limitations. First, the precise assessment of CIK cell-induced treatment might be limited by the patient selection bias in the retrospective study. Second, the data collected in this study spanned from January 1, 2009 to January 1, 2015 and the follow-up period was up to May 1, 2018. The short follow-up time did not reflect the effect of CIK cell therapy on the long-term survival of patients with TNBC after surgery. A previous study revealed that CIK cells have a long half-life *in vivo*^[@b43]^, which could explain the long-lasting effects of CIK cells. Even if the disease progresses, the remaining active CIK cells can eliminate tumor cells and slow down the disease progression. Therefore, a prospective, multi-center, long-lasting follow-up assessment of CIK cell therapy for TNBC is required.

. Conclusions {#s05}
=============

In summary, the strategy of CIK cell therapy after adjuvant chemotherapy could reduce recurrence and metastasis in postoperative TNBC patients, thereby prolong the overall survival time with minimum side effects. Therefore, CIK cell immunotherapy could be a potential new strategy for systemic adjuvant therapy after surgery for TNBC patients in the near future. Recently, the development of a gene expression profile facilitated re-classification of TNBC into six new subtypes, which showed varied sensitivities to different therapies. As precision medicine develops, precision therapy may be directed at various, potentially actionable molecular mutations in different subtypes of TNBC.
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###### 

Clinical characteristics of patients in the two groups

  Patient   Group           Age, years   TNM stage         Lymph node   Pathological grades   Radiotherapy   Recurrence   Survival
  --------- --------------- ------------ ----------------- ------------ --------------------- -------------- ------------ ----------
  1         CIK group       77           IIb               Positive     III                   No             Yes          Alive
  2         CIK group       52           IIa               Positive     II                    Yes            No           Alive
  3         CIK group       38           Unable to value   Positive     III                   No             No           Alive
  4         CIK group       60           I                 Negative     II                    No             No           Alive
  5         CIK group       58           I                 Positive     III                   Yes            No           Alive
  6         CIK group       60           Unable to value   Negative     III                   No             No           Alive
  7         CIK group       37           IIb               Negative     II                    No             No           Alive
  8         CIK group       49           I                 Negative     II                    No             No           Alive
  9         CIK group       51           I                 Negative     II                    No             No           Alive
  10        CIK group       50           IIIa              Positive     II                    Yes            No           Alive
  11        CIK group       60           I                 Negative     II                    No             No           Alive
  12        CIK group       61           IIa               Negative     II                    No             No           Alive
  13        CIK group       76           IIa               Negative     II                    No             No           Alive
  14        CIK group       46           I                 Negative     II                    No             No           Alive
  15        CIK group       54           IIa               Positive     II                    Yes            No           Alive
  16        CIK group       64           IIb               Positive     II                    No             No           Alive
  17        CIK group       58           IIb               Positive     II                    No             No           Alive
  18        CIK group       44           IIb               Positive     III                   Yes            No           Alive
  19        CIK group       50           I                 Negative     III                   No             No           Alive
  20        CIK group       33           IIb               Negative     II                    No             No           Alive
  21        CIK group       57           IIIc              Positive     III                   Yes            Yes          Death
  22        CIK group       52           Unable to value   Negative     III                   No             No           Alive
  23        CIK group       56           IIa               Positive     II                    Yes            No           Alive
  24        CIK group       38           I                 Negative     II                    No             No           Alive
  25        CIK group       33           IIa               Negative     III                   No             No           Alive
  26        CIK group       51           IIb               Positive     III                   No             No           Alive
  27        CIK group       58           IIIc              Positive     III                   No             No           Alive
  28        CIK group       53           IIIc              Positive     II                    No             Yes          Alive
  29        CIK group       40           IIa               Negative     II                    Yes            No           Alive
  30        CIK group       54           IIa               Negative     II                    No             No           Alive
  31        CIK group       56           IIa               Positive     III                   Yes            No           Alive
  32        CIK group       51           I                 Negative     II                    No             No           Alive
  33        CIK group       53           IIa               Positive     III                   No             No           Alive
  34        CIK group       56           IIa               Negative     II                    No             No           Alive
  35        CIK group       59           I                 Negative     II                    No             No           Alive
  36        CIK group       66           IIa               Negative     II                    No             No           Alive
  37        CIK group       56           I                 Negative     II                    No             No           Alive
  38        CIK group       42           IIb               Positive     III                   Yes            Yes          Death
  39        CIK group       50           IIa               Negative     III                   No             No           Alive
  40        CIK group       49           I                 Negative     II                    No             No           Alive
  41        CIK group       69           I                 Negative     III                   No             No           Alive
  42        CIK group       47           IIa               Negative     II                    No             No           Alive
  43        CIK group       55           I                 Positive     II                    No             No           Alive
  44        CIK group       50           IIa               Negative     II                    No             No           Alive
  45        CIK group       59           I                 Negative     III                   No             No           Alive
  46        CIK group       59           IIa               Positive     II                    No             No           Alive
  47        CIK group       50           IIIc              Positive     III                   No             No           Alive
  48        CIK group       56           Unable to value   Positive     III                   Yes            No           Alive
  49        CIK group       57           I                 Negative     II                    No             No           Alive
  50        CIK group       60           IIa               Negative     II                    No             No           Alive
  51        CIK group       63           I                 Negative     II                    No             No           Alive
  52        CIK group       62           IIa               Positive     II                    Yes            No           Alive
  53        CIK group       60           I                 Negative     III                   No             No           Alive
  54        CIK group       54           IIa               Negative     III                   No             No           Alive
  55        CIK group       48           IIb               Positive     II                    No             No           Alive
  56        CIK group       58           IIa               Negative     II                    No             No           Alive
  57        CIK group       31           I                 Negative     III                   Yes            No           Alive
  58        CIK group       56           IIa               Positive     II                    Yes            No           Alive
  59        CIK group       60           IIa               Positive     II                    No             No           Alive
  60        CIK group       52           I                 Negative     II                    No             No           Alive
  61        CIK group       42           IIIc              Positive     III                   Yes            Yes          Death
  62        CIK group       52           IIa               Negative     III                   No             No           Alive
  63        CIK group       53           I                 Negative     II                    No             No           Alive
  64        CIK group       61           IIIa              Positive     II                    Yes            No           Alive
  65        CIK group       48           IIa               Positive     II                    No             No           Alive
  66        CIK group       34           I                 Negative     III                   No             No           Alive
  67        CIK group       71           IIb               Negative     II                    No             No           Alive
  68        CIK group       48           Unable to value   Negative     II                    No             Yes          Alive
  69        CIK group       46           I                 Negative     II                    No             No           Alive
  70        CIK group       37           IIb               Negative     II                    Yes            No           Alive
  71        CIK group       45           IIIa              Positive     II                    No             No           Alive
  72        CIK group       61           IIa               Negative     II                    No             No           Alive
  73        CIK group       45           IIIc              Positive     III                   Yes            Yes          Death
  74        CIK group       56           I                 Negative     III                   No             No           Alive
  75        CIK group       59           IIa               Negative     II                    No             No           Alive
  76        CIK group       46           IIa               Negative     II                    No             No           Alive
  77        CIK group       41           I                 Negative     II                    No             No           Alive
  78        CIK group       46           IIb               Positive     III                   No             No           Alive
  79        CIK group       49           IIa               Negative     III                   No             No           Alive
  80        CIK group       54           I                 Negative     III                   No             No           Alive
  81        CIK group       61           IIb               Positive     III                   Yes            No           Alive
  82        CIK group       49           IIa               Negative     II                    No             No           Alive
  83        CIK group       55           I                 Negative     II                    No             No           Alive
  84        CIK group       50           IIa               Negative     II                    Yes            Yes          Death
  85        CIK group       46           I                 Negative     II                    No             No           Alive
  86        CIK group       57           IIIb              Positive     II                    Yes            No           Alive
  87        CIK group       33           IIb               Positive     III                   No             No           Alive
  88        CIK group       61           IIa               Negative     III                   No             No           Alive
  89        CIK group       52           I                 Negative     III                   No             No           Alive
  90        CIK group       47           IIa               Negative     II                    Yes            No           Alive
  91        CIK group       58           IIIa              Positive     II                    Yes            No           Alive
  92        CIK group       45           IIa               Negative     II                    No             No           Alive
  93        CIK group       53           I                 Negative     II                    No             No           Alive
  94        CIK group       32           IIa               Negative     III                   Yes            Yes          Alive
  95        CIK group       38           IIa               Positive     III                   Yes            No           Alive
  96        CIK group       31           Unable to value   Negative     III                   Yes            Yes          Death
  97        CIK group       50           IIb               Negative     III                   No             No           Alive
  98        CIK group       44           IIb               Negative     II                    No             No           Alive
  99        CIK group       62           IIa               Positive     III                   No             No           Alive
  100       CIK group       54           I                 Negative     II                    Yes            No           Alive
  101       CIK group       50           IIa               Positive     II                    No             No           Alive
  102       CIK group       68           I                 Negative     III                   No             No           Alive
  103       CIK group       26           Unable to value   Negative     II                    Yes            No           Alive
  104       CIK group       60           IIa               Negative     II                    No             No           Alive
  105       CIK group       35           IIb               Positive     II                    No             No           Alive
  106       CIK group       36           IIa               Negative     II                    No             No           Alive
  107       CIK group       52           IIb               Positive     III                   Yes            No           Alive
  108       CIK group       60           IIa               Negative     II                    No             No           Alive
  109       CIK group       43           IIa               Negative     III                   No             No           Alive
  110       CIK group       57           IIa               Positive     III                   No             No           Alive
  111       CIK group       73           IIIa              Positive     III                   No             No           Alive
  112       CIK group       72           IIa               Negative     II                    No             No           Alive
  113       CIK group       47           IIa               Negative     III                   No             No           Alive
  114       CIK group       49           IIa               Negative     III                   No             Yes          Alive
  115       CIK group       40           I                 Negative     II                    No             No           Alive
  116       CIK group       52           IIb               Positive     III                   No             Yes          Alive
  117       CIK group       38           IIb               Positive     III                   Yes            No           Alive
  118       CIK group       53           IIa               Negative     III                   No             No           Alive
  119       CIK group       50           IIa               Negative     II                    No             No           Alive
  120       CIK group       57           I                 Negative     II                    No             Yes          Alive
  121       CIK group       54           IIa               Positive     III                   No             No           Alive
  122       CIK group       50           IIb               Positive     III                   Yes            No           Alive
  123       CIK group       64           I                 Negative     II                    No             No           Alive
  124       CIK group       61           I                 Negative     II                    No             No           Alive
  125       CIK group       49           I                 Negative     II                    Yes            No           Alive
  126       CIK group       59           I                 Negative     II                    No             No           Alive
  127       CIK group       68           IIb               Positive     II                    No             No           Alive
  128       CIK group       59           IIb               Positive     III                   No             No           Alive
  129       CIK group       59           IIa               Negative     III                   No             No           Alive
  130       CIK group       48           IIa               Negative     II                    No             Yes          Alive
  131       CIK group       53           I                 Negative     II                    No             No           Alive
  132       CIK group       60           I                 Negative     III                   No             No           Alive
  133       CIK group       45           IIIc              Positive     III                   Yes            Yes          Death
  134       CIK group       60           I                 Negative     II                    No             No           Alive
  135       CIK group       69           IIIc              Positive     II                    Yes            Yes          Death
  136       CIK group       45           IIa               Negative     III                   No             No           Alive
  137       CIK group       39           I                 Negative     II                    No             No           Alive
  138       CIK group       42           I                 Negative     II                    No             No           Alive
  139       CIK group       44           I                 Negative     III                   Yes            No           Alive
  140       CIK group       44           I                 Negative     II                    Yes            No           Alive
  141       CIK group       32           IIa               Positive     II                    Yes            No           Alive
  142       CIK group       55           I                 Negative     III                   No             No           Alive
  143       CIK group       43           IIa               Negative     II                    No             Yes          Death
  144       CIK group       40           IIa               Negative     II                    No             No           Alive
  145       CIK group       64           IIa               Negative     II                    No             No           Alive
  146       CIK group       69           IIIc              Positive     II                    Yes            Yes          Death
  147       CIK group       44           IIa               Negative     II                    No             No           Alive
  148       Control group   78           I                 Negative     II                    No             No           Alive
  149       Control group   76           I                 Negative     II                    No             No           Alive
  150       Control group   73           I                 Negative     II                    No             No           Alive
  151       Control group   72           IIb               Positive     III                   No             No           Alive
  152       Control group   71           IIIc              Positive     III                   No             Yes          Death
  153       Control group   69           IIb               Positive     III                   No             Yes          Death
  154       Control group   69           IIIa              Positive     II                    Yes            Yes          Death
  155       Control group   69           IIIb              Negative     III                   No             No           Alive
  156       Control group   68           I                 Negative     III                   No             No           Alive
  157       Control group   68           I                 Negative     II                    Yes            No           Alive
  158       Control group   66           I                 Negative     II                    No             No           Alive
  159       Control group   64           I                 Negative     II                    Yes            No           Alive
  160       Control group   64           IIb               Positive     II                    No             No           Alive
  161       Control group   64           IIa               Negative     II                    No             No           Alive
  162       Control group   63           Unable to value   Negative     III                   No             No           Alive
  163       Control group   62           IIa               Positive     II                    No             No           Alive
  164       Control group   62           IIa               Negative     III                   Yes            No           Alive
  165       Control group   61           IIa               Negative     II                    No             No           Alive
  166       Control group   61           IIa               Positive     III                   Yes            Yes          Death
  167       Control group   61           IIIa              Positive     II                    Yes            Yes          Death
  168       Control group   61           IIa               Negative     II                    No             No           Alive
  169       Control group   61           IIa               Negative     I                     No             No           Alive
  170       Control group   61           IIb               Positive     II                    Yes            No           Alive
  171       Control group   61           IIa               Negative     II                    No             No           Alive
  172       Control group   60           I                 Negative     II                    No             No           Alive
  173       Control group   60           IIa               Negative     II                    No             No           Alive
  174       Control group   60           IIIc              Positive     II                    No             No           Alive
  175       Control group   60           IIa               Negative     III                   No             No           Alive
  176       Control group   60           IIIa              Positive     II                    Yes            Yes          Death
  177       Control group   60           IIIc              Positive     II                    No             No           Alive
  178       Control group   60           IIIc              Positive     III                   Yes            Yes          Death
  179       Control group   60           IIIc              Positive     II                    Yes            Yes          Death
  180       Control group   60           Unable to value   Positive     III                   No             No           Alive
  181       Control group   59           IIIc              Positive     II                    No             No           Alive
  182       Control group   59           IIb               Positive     III                   No             No           Alive
  183       Control group   59           IIa               Positive     II                    No             No           Alive
  184       Control group   59           I                 Negative     III                   No             No           Alive
  185       Control group   59           IIa               Positive     II                    No             Yes          Death
  186       Control group   59           IIa               Positive     II                    No             No           Alive
  187       Control group   59           IIa               Negative     II                    Yes            No           Alive
  188       Control group   58           IIb               Negative     II                    Yes            No           Alive
  189       Control group   58           IIa               Positive     II                    No             No           Alive
  190       Control group   58           IIa               Negative     II                    No             No           Alive
  191       Control group   58           IIIa              Positive     II                    Yes            No           Alive
  192       Control group   58           IIa               Negative     II                    Yes            No           Alive
  193       Control group   56           I                 Negative     II                    No             No           Alive
  194       Control group   57           I                 Negative     II                    No             Yes          Alive
  195       Control group   57           IIIa              Positive     III                   No             No           Alive
  196       Control group   57           I                 Negative     II                    Yes            No           Alive
  197       Control group   57           IIa               Negative     III                   No             No           Alive
  198       Control group   56           IIIc              Positive     II                    No             No           Alive
  199       Control group   56           IIIa              Positive     III                   No             No           Alive
  200       Control group   56           IIIb              Negative     III                   No             Yes          Death
  201       Control group   56           I                 Negative     III                   No             Yes          Death
  202       Control group   56           IIa               Negative     II                    Yes            No           Alive
  203       Control group   56           I                 Negative     III                   No             No           Alive
  204       Control group   56           IIa               Negative     III                   No             No           Alive
  205       Control group   55           IIa               Positive     III                   No             No           Alive
  206       Control group   55           IIa               Positive     III                   Yes            No           Alive
  207       Control group   55           I                 Negative     III                   No             Yes          Death
  208       Control group   54           I                 Negative     II                    No             No           Alive
  209       Control group   54           I                 Negative     III                   No             No           Alive
  210       Control group   54           IIa               Positive     II                    No             No           Alive
  211       Control group   54           IIIc              Positive     II                    No             Yes          Death
  212       Control group   54           IIa               Negative     II                    No             No           Alive
  213       Control group   54           IIIa              Positive     II                    Yes            No           Alive
  214       Control group   53           IIIc              Positive     II                    No             Yes          Death
  215       Control group   53           IIa               Negative     II                    No             Yes          Death
  216       Control group   53           I                 Negative     II                    No             No           Alive
  217       Control group   53           IIa               Positive     II                    No             Yes          Death
  218       Control group   53           I                 Negative     III                   No             Yes          Death
  219       Control group   53           IIa               Positive     II                    No             No           Alive
  220       Control group   52           IIa               Negative     II                    No             No           Alive
  221       Control group   52           I                 Negative     II                    No             No           Alive
  222       Control group   52           IIa               Negative     II                    No             No           Alive
  223       Control group   52           I                 Negative     II                    Yes            Yes          Alive
  224       Control group   52           IIa               Positive     II                    No             No           Alive
  225       Control group   52           I                 Negative     III                   Yes            No           Alive
  226       Control group   52           I                 Negative     II                    No             No           Alive
  227       Control group   51           I                 Negative     II                    No             No           Alive
  228       Control group   51           IIa               Positive     III                   No             No           Alive
  229       Control group   51           I                 Negative     II                    Yes            No           Alive
  230       Control group   50           IIa               Negative     III                   No             No           Alive
  231       Control group   50           IIb               Positive     II                    No             No           Alive
  232       Control group   50           IIa               Negative     II                    No             Yes          Alive
  233       Control group   50           IIIc              Positive     III                   No             No           Alive
  234       Control group   50           IIa               Positive     III                   No             No           Alive
  235       Control group   50           I                 Negative     III                   No             No           Alive
  236       Control group   50           IIIc              Positive     II                    Yes            Yes          Death
  237       Control group   50           Unable to value   Negative     I                     No             No           Alive
  238       Control group   50           I                 Negative     II                    No             No           Alive
  239       Control group   50           I                 Negative     III                   No             No           Alive
  240       Control group   49           IIa               Negative     III                   No             No           Alive
  241       Control group   49           IIIc              Positive     III                   Yes            Yes          Death
  242       Control group   49           I                 Negative     III                   No             No           Alive
  243       Control group   49           I                 Negative     II                    No             No           Alive
  244       Control group   49           IIa               Negative     II                    No             No           Alive
  245       Control group   49           I                 Negative     II                    No             No           Alive
  246       Control group   48           IIIa              Positive     II                    Yes            Yes          Alive
  247       Control group   48           IIa               Negative     II                    No             No           Alive
  248       Control group   48           IIa               Negative     II                    No             No           Alive
  249       Control group   48           IIb               Positive     III                   No             Yes          Death
  250       Control group   47           I                 Negative     II                    No             No           Alive
  251       Control group   47           IIa               Positive     II                    Yes            No           Alive
  252       Control group   47           IIa               Negative     III                   No             No           Alive
  253       Control group   46           I                 Negative     II                    No             No           Alive
  254       Control group   46           I                 Negative     II                    No             No           Alive
  255       Control group   46           IIIc              Positive     II                    No             No           Alive
  256       Control group   46           I                 Negative     III                   No             No           Alive
  257       Control group   46           IIa               Positive     II                    No             No           Alive
  258       Control group   45           IIa               Negative     III                   No             No           Alive
  259       Control group   45           I                 Negative     III                   No             No           Alive
  260       Control group   45           IIIa              Positive     II                    No             No           Alive
  261       Control group   45           I                 Negative     II                    No             No           Alive
  262       Control group   45           IIIa              Positive     III                   Yes            No           Alive
  263       Control group   44           IIa               Positive     II                    No             No           Alive
  264       Control group   44           IIa               Negative     II                    No             Yes          Death
  265       Control group   44           IIa               Negative     II                    No             No           Alive
  266       Control group   44           I                 Negative     III                   No             No           Alive
  267       Control group   44           IIa               Negative     III                   No             No           Alive
  268       Control group   43           I                 Negative     III                   No             No           Alive
  269       Control group   43           IIa               Positive     II                    No             No           Alive
  270       Control group   42           IIIa              Positive     III                   No             No           Alive
  271       Control group   42           IIa               Negative     III                   No             No           Alive
  272       Control group   42           IIa               Positive     II                    No             No           Alive
  273       Control group   41           IIa               Negative     II                    No             No           Alive
  274       Control group   40           IIa               Negative     III                   No             Yes          Death
  275       Control group   40           I                 Negative     II                    No             No           Alive
  276       Control group   40           Unable to value   Negative     III                   No             No           Alive
  277       Control group   39           IIa               Negative     II                    No             No           Alive
  278       Control group   38           IIb               Positive     III                   No             No           Alive
  279       Control group   38           Unable to value   Negative     II                    No             No           Alive
  280       Control group   38           IIIa              Positive     II                    No             No           Alive
  281       Control group   38           IIa               Positive     III                   No             Yes          Death
  282       Control group   37           IIIa              Positive     II                    No             Yes          Death
  283       Control group   37           IIIc              Positive     III                   No             No           Alive
  284       Control group   36           IIb               Positive     III                   Yes            Yes          Death
  285       Control group   35           IIIa              Positive     II                    No             Yes          Alive
  286       Control group   34           IIb               Positive     II                    No             No           Alive
  287       Control group   33           I                 Negative     III                   No             No           Alive
  288       Control group   33           IIa               Positive     II                    No             No           Alive
  289       Control group   33           IIIc              Positive     III                   Yes            No           Alive
  290       Control group   32           I                 Negative     II                    No             No           Alive
  291       Control group   32           Unable to value   Negative     II                    No             No           Alive
  292       Control group   31           I                 Negative     III                   No             No           Alive
  293       Control group   31           IIa               Negative     III                   No             No           Alive
  294       Control group   26           IIa               Negative     III                   No             Yes          Death
